The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will ...
Clinical Trials Arena on MSN13h
IGC Pharma posts promising interim data for Alzheimer’s therapyThe results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.
Top health care investment bankers say that large deals involving pharmaceutical and biotech companies are stalling as executives grapple with ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast ...
Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...
Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback